Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study
- PMID: 32939583
- DOI: 10.1007/s00592-020-01605-6
Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study
Abstract
Introduction: Emerging evidence suggests that HbA1c variability, in addition to HbA1c itself, can be used as a predictor for mortality. The present study aims to examine the predictive power of mean HbA1c and HbA1c variability measures for diabetic complications as well as mortality.
Methods: The retrospective observational study analyzed diabetic patients who were prescribed insulin at outpatient clinics of the Prince of Wales Hospital and Shatin Hospital, Hong Kong, from 1 January to 31 December, 2009. Standard deviation (SD), root mean square (RMS), and coefficient of variation were used as measures of HbA1c variability. The primary outcomes were all-cause and cardiovascular mortality. Secondary outcomes were diabetes-related complications.
Results: The study cohort consists of 3424 patients, including 3137 patients with at least three HbA1c measurements. The low mean HbA1c subgroup had significantly shorter time-to-death for all-cause mortality (P < 0.001) but not cardiovascular mortality (P = 0.920). The high Hba1c subgroup showed shorter time-to-death for all-cause (P < 0.001) and cardiovascular mortality (P < 0.001). Mean Hba1c and Hba1c variability predicted all-cause as well as cardiovascular-specific mortality. In terms of secondary outcomes, mean HbA1c and HbA1c variability significantly predicted diabetic ketoacidosis/hyperosmolar hyperglycemic state/diabetic coma, neurological, ophthalmological, and renal complications. A significant association between dichotomized HbA1c variability and hypoglycemia frequency was found (P < 0.0001).
Conclusion: High HbA1c variability is associated with increased risk of all-cause and cardiovascular mortality, as well as diabetic complications. The association between hypoglycemic frequency, HbA1c variability, and mortality suggests that intermittent hypoglycemia resulting in poorer outcomes in diabetic patients.
References
-
- Saeedi P, Petersohn I, Salpea P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 157:107843. https://doi.org/10.1016/j.diabres.2019.107843 - DOI - PubMed
-
- King P, Peacock I, Donnelly R (1999) The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 48(5):643–648. https://doi.org/10.1046/j.1365-2125.1999.00092.x - DOI - PubMed - PMC
-
- Heller SR, Group AC (2009) A summary of the advance trial. Diabetes Care 32(Suppl 2):S357–S361. https://doi.org/10.2337/dc09-S339 - DOI - PubMed - PMC
-
- Huang ES, Davis AM (2015) Glycemic control in older adults with diabetes mellitus. JAMA 314(14):1509–1510. https://doi.org/10.1001/jama.2015.8345 - DOI - PubMed - PMC
-
- Buse JB, Bigger JT et al (2007) Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol. 99(12A):21i–33i. https://doi.org/10.1016/j.amjcard.2007.03.003 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical